Format

Send to:

Choose Destination
See comment in PubMed Commons below
Sci Transl Med. 2012 Jun 20;4(139):139ra85. doi: 10.1126/scitranslmed.3003921.

Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy.

Author information

  • 1Department of Physiology and Biophysics, Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA. noah.weisleder@umdnj.edu

Abstract

Mitsugumin 53 (MG53), a muscle-specific TRIM family protein, is an essential component of the cell membrane repair machinery. Here, we examined the translational value of targeting MG53 function in tissue repair and regenerative medicine. Although native MG53 protein is principally restricted to skeletal and cardiac muscle tissues, beneficial effects that protect against cellular injuries are present in nonmuscle cells with overexpression of MG53. In addition to the intracellular action of MG53, injury to the cell membrane exposes a signal that can be detected by MG53, allowing recombinant MG53 protein to repair membrane damage when provided in the extracellular space. Recombinant human MG53 (rhMG53) protein purified from Escherichia coli fermentation provided dose-dependent protection against chemical, mechanical, or ultraviolet-induced damage to both muscle and nonmuscle cells. Injection of rhMG53 through multiple routes decreased muscle pathology in the mdx dystrophic mouse model. Our data support the concept of targeted cell membrane repair in regenerative medicine, and present MG53 protein as an attractive biological reagent for restoration of membrane repair defects in human diseases.

Comment in

PMID:
22723464
[PubMed - indexed for MEDLINE]
PMCID:
PMC3777623
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk